CompoAtlas

MAUX DE TÊTE

Food supplement declared in France, decision dated 20 December 2024

MAUX DE TÊTE is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). None of the rules we check flags an issue with its declared composition.

Brand
not provided
Food business operator placing the product on the market
SAS RDV
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Flacon
Daily dose
3 cuillères à café
Directions for use
1 cuillère à café dans un verre d’eau, 3 fois par jour.
Intended populations
Hommes et femmes de 18 ans et plus
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Autre : MAUX DE TÊTE, Femmes enceintes, Problèmes de foie, Ulcère (estomac ou duodenum)
Objectives stated by the manufacturer (these are not authorised claims)
Autre : MAUX DE TÊTE

Declaration 2029, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

None of the rules we check applies to the declared ingredients.

Declared composition

Plants

PlantPartPreparationPer day
Citrus limon (L.) Burm. f.FeuilleExtrait fluide hydroalcoolique95 mg
Cynara scolymus L.Parties aériennesExtrait fluide hydroalcoolique95 mg
Levisticum officinale W.D.J. KochPlante entièreExtrait fluide hydroalcoolique95 mg
Apium graveolens L.Plante entièreExtrait fluide hydroalcoolique95 mg
Mentha x piperita L.Parties aériennesExtrait fluide hydroalcoolique95 mg

Other active ingredients

NamePer day
mielnot declared

Additives

E422

Other ingredients

Alcool éthylique, Eau purifiée

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Réservé à l'adulte. Déconseillé en cas d'obstruction biliaire et de trouble de la fonction biliaire. Déconseillé en cas d'allergie croisée connue aux plantes de la famille des Astéracée, des Apiacées, au menthol et a l'anéthol. Déconseillé en cas de reflux gastro-oesophagien, d'ulcère gastroduodénal, de gastrite ou de trouble biliaire ou hépatiques. Déconseillé aux femmes enceintes et allaitantes.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Mentha x piperita L.
    Read the warning, when it applies and the studies cited

    PEPPERMINT - MENTHA X PIPERITA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gallstones or anemia (Brinker 2010; Mills and Bone 2005; Blumenthal et al. 2000).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Essential oil.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have hiatus hernia or gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: Essential oil.

    When using this product you may experience gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Stop use if hypersensitivity/allergy occurs (Mills and Bone 2005; ESCOP 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 27 February 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line